

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/148370 A1

(43) International Publication Date
14 July 2022 (14.07.2022)

(51) International Patent Classification:

C07K 16/28 (2006.01) *A61P 35/00* (2006.01)
A61K 39/395 (2006.01) *A61K 35/17* (2015.01)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/CN2022/070287

(22) International Filing Date:

05 January 2022 (05.01.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2021/070314

05 January 2021 (05.01.2021) CN

(71) Applicant: **LANOVA MEDICINES DEVELOPMENT CO., LTD.** [CN/CN]; No. 177, Group 6, Rennan Village, Kangqiao Town, Pudong New District, Shanghai 201315 (CN).

(72) Inventors: **LI, Runsheng**; No. 177, Group 6, Rennan Village, Kangqiao Town, Pudong New District, Shanghai 201315 (CN). **HUANG, Wentao**; No. 177, Group 6, Rennan Village, Kangqiao Town, Pudong New District, Shanghai 201315 (CN).

(74) Agent: **SINO-CREATIVITY INTELLECTUAL PROPERTY LAW FIRM**; Room 25A3-1, East Wing, Hanwei Plaza No.7 Guanghua Road, Chaoyang District, Beijing 100020 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTI-GPRC5D MONOCLONAL ANTIBODIES AND USES THEREOF

(57) Abstract: Provided are antibodies or fragments thereof having binding specificity to the human GPRC5D protein. The antibodies or fragments thereof are capable of targeting cancer cells expressing GPRC5D, and thus can be used to treat the cancer, in particular hematological cancer.



WO 2022/148370 A1